Core Viewpoint - Ventripoint Diagnostics Ltd. will fulfill its debenture interest payment obligations by issuing common shares, pending approval from the TSX Venture Exchange [1] Group 1: Financial Details - The company will issue a total of 1,145,627 common shares to cover $103,106.29 in interest on outstanding Convertible Debentures [1] - The Convertible Debentures carry an interest rate of 10% per annum, with payments due every six months [1] - The shares will be issued at a deemed price of $0.089 and will be subject to a hold period of 4 months and one day [1] Group 2: Company Overview - Ventripoint has established itself as a leader in applying AI to echocardiography, with its VMS products utilizing proprietary knowledge-based reconstruction technology [2] - This technology provides accurate volumetric cardiac measurements comparable to MRI, offering a cost-effective alternative for cardiologists [2] - VMS+ is compatible with all ultrasound systems from various vendors and has received regulatory market approvals in the U.S., Europe, and Canada [2]

Key Takeaways HOLX said its Genius AI flagged 32% of false-negative mammograms and identified cancer hidden in dense tissue.Researchers reviewed 7,500 3D exams and found HOLX AI detected nearly 90% of cancers seen by radiologists.HOLX noted the study shows AI's potential to boost early detection and strengthen future breast imaging tools.Hologic, Inc. (HOLX) recently announced the latest clinical evidence showing the effectiveness of its Genius AI-based mammography screening technology in improving breast c ...

Core Insights - Hologic's AI-powered mammography solutions are gaining traction in clinical settings, particularly with the 3DQuorum technology, which enhances radiologists' workflows and maintains high cancer detection effectiveness [1] - The Genius AI Detection solution has demonstrated comparable performance to radiologists in identifying challenging breast cancer cases, with new data indicating its potential to increase cancer detection rates [1][9] Technology Performance - A study involving 7,500 digital breast tomosynthesis exams revealed that the Genius AI Detection solution flagged approximately 32% of false-negative mammograms, accurately identifying the location of breast cancer in one-third of these cases [2][3][9] - The AI technology successfully flagged nearly 90% of previously identified breast cancer cases by radiologists, showing a higher likelihood of detecting invasive ductal carcinomas and lymph node-positive cancers [4] Study Limitations - The study's findings may not be generalizable due to its single-center design, predominantly Caucasian patient population, and the use of a specific version of the AI software, which limits the applicability of results to other settings or algorithms [5] Industry Updates - GE Healthcare announced a contract to supply over 300 CT scanners to Indonesia, aiming to improve healthcare access for over 280 million people [6] - Becton, Dickinson and Company is expanding its diagnostic offerings in Europe, focusing on respiratory and STI diagnostics with new assays developed in partnership with Certest Biotec [7] Stock Performance and Valuation - Hologic's stock has increased by 10% over the past three months, outperforming the industry growth of 8.6% [8] - The company is currently trading at a forward five-year price-to-sales ratio of 3.86X, which is lower than the industry average of 4.36X [10]

Core Insights - Lifeward Ltd. has entered into a distribution agreement with Verita Neuro to expand access to the ReWalk Personal Exoskeleton for spinal cord injury patients, targeting a total addressable market of approximately $1.75 billion [1][3] Group 1: Distribution Agreement - The agreement allows Verita Neuro to be the exclusive distributor of ReWalk in Mexico, Thailand, and the UAE, leveraging its established international presence [1][3] - Verita Neuro has a database of over 25,000 spinal cord injury patients and a network of rehabilitation centers, enhancing the reach of ReWalk [2] Group 2: Commercial Strategy - Lifeward's hybrid commercial model combines direct sales in the U.S. with third-party distribution in select international markets, aiming for increased sales volumes while managing operating expenses [3] - The partnership with Verita Neuro is intended to integrate ReWalk into their multi-modal treatment methodologies, which include surgical neural stimulation and stem cell therapy [3][4] Group 3: Rehabilitation Approach - Verita Neuro will implement a new delivery model that includes intensive in-patient training and rehabilitation for ReWalk, differing from the traditional outpatient training [4] - This approach is expected to enhance clinical adoption of ReWalk in various rehabilitation settings globally [4]

Core Viewpoint - Three stocks have been added to the Zacks Rank 5 (Strong Sell) List, indicating a negative outlook for these companies based on recent earnings estimate revisions [1][2]. Company Summaries - **Avanos Medical, Inc. (AVNS)**: This medical technology company has seen its current year earnings estimate revised downward by 3.3% over the last 60 days [1]. - **Archer-Daniels-Midland Company (ADM)**: An agricultural commodities and ingredients company, ADM's current year earnings estimate has been revised downward by 8.6% over the last 60 days [1]. - **Bank OZK (OZK)**: This company provides retail and commercial banking services, with its current year earnings estimate revised downward by 3.4% over the last 60 days [2].

REGENSBURG, Germany, Dec. 17, 2025 /PRNewswire/ -- numares Health ("numares"), the transformative metabolomics company pioneering multidimensional biomarker insights that deliver clinical pathways for optimal patient care, today announces the expansion of its global footprint into the ASEAN region having received regulatory approval in Malaysia and subsequently securing its first contract for the AXINON® LDLp Test System ("AXINON") with BioD Medica, who specialise in introducing medical devices and healthca ...

PresentationRobert SassoonWater Tower Research LLC Hello, everybody. I'm Robert Sassoon, healthcare analyst at Water Tower Research. I have the double pleasure of hosting Kirk Huntsman, CEO of Vivos Therapeutics; and Brad Amman, the company's CFO, for this fireside chat. Vivos is a revenue stage medical technology company focused on developing and commercializing a suite of innovative diagnostic and nonsurgical treatment methods for patients suffering from breathing and sleep issues arising from certain de ...

Core Viewpoint - KORU Medical Systems, Inc. has appointed Eric Schiller as Chief Technology Officer, effective December 29, 2025, bringing over 25 years of leadership experience in research and development [1] Company Overview - KORU Medical is a leading medical technology company focused on developing, manufacturing, and commercializing innovative and patient-centric large volume subcutaneous infusion solutions [1] Leadership Change - The appointment of Eric Schiller is expected to enhance the company's technological capabilities and innovation in the medical technology sector [1] Future Outlook - The company aims to leverage Schiller's extensive experience to drive advancements in its product offerings and improve patient care solutions [1]

CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting at the J.P. Morgan 2026 Healthcare conference on Wednesday, January 14th at 4:30-5:10 pm PT in San Francisco, CA. During the conference, Carlsmed Management will be hosting 1x1 investor meetings. About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery soluti ...

Core Insights - Riverwater Partners' Small Cap Strategy reported solid results for Q3 2025 but lagged behind the benchmark due to the market's preference for lower-quality companies [1] - The strategy focuses on higher-quality companies with strong fundamentals and a clear path to profitability, positioning itself well in a challenging market [1] Company Performance - Haemonetics Corporation (NYSE:HAE) had a one-month return of 8.06% but experienced a 2.03% decline over the last 52 weeks, closing at $80.40 per share with a market capitalization of $3.873 billion [2] - The company faced challenges due to softer-than-expected demand in certain product lines, leading to a decision to exit the position in Q3 2025 to redeploy capital into opportunities with clearer near-term catalysts [3] Revenue and Market Position - In Q2 of fiscal 2026, Haemonetics reported revenue of $327 million, reflecting a 5% decline [4] - Despite its potential, Haemonetics is not among the most popular stocks among hedge funds, with 36 hedge fund portfolios holding its shares at the end of Q3, up from 29 in the previous quarter [4]